| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S84361-1mg促销 |
≥98% | ￥400.00 ￥360.00 |
10 | - | - | - | - |
|
S84361-5mg促销 |
≥98% | ￥1000.00 ￥900.00 |
10 | - | - | - | - |
|
S84361-10mg促销 |
≥98% | ￥2200.00 ￥1980.00 |
9 | - | - | - | - |
|
S84361-25mg促销 |
≥98% | ￥4000.00 ￥3600.00 |
2 | - | - | - | - |
|
S84361-50mg促销 |
≥98% | ￥5700.00 ￥5130.00 |
3 | - | - | - | - |
|
S84361-100mg促销 |
≥98% | ￥8000.00 ￥7200.00 |
1 | - | - | - | - |
|
| 产品描述： | Nastorazepide is a selective, orally available antagonist of gastrin/cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | cholecystokinin | ||||||||||||||||||||
| 体外研究： | Nastorazepide binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells | ||||||||||||||||||||
| 体内研究： | Nastorazepide significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Nastorazepide combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice | ||||||||||||||||||||
| 参考文献： | 1. Kato H, et al. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京